Drugs / NK Cell Infusion
last change Jul 2019 re-read 2 minutes ago

NK Cell Infusion

Cell therapy

Developed for
leukemia · lymphoma
Investigated by
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · M.D. Anderson Cancer Center

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00383994 Sep 2006 → Jul 2019 disease related to transplantation, leukemia, lymphoma M.D. Anderson Cancer Center Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NK Cell Infusion ClinicalTrials.gov intervention name — accepted as the source's own label NCT00383994
Modality Cell therapy “a boost of natural killer (NK) cells from a donor” NCT00383994
Route Intravenous “These cells will be infused through a vein” NCT00383994